Key result
Disease stage, tumors >5 cm, and grade 3 predict worse survival in synovial sarcoma.
Population
45 patients with synovial sarcoma, median age 31 years, 56% male, diagnosed between 1984 and 2005.
Design
Cohort
Follow-up
median 55 months (range: 2 to 238)
Authors
Loading...
Supports reliance on stage, size, and grade for synovial sarcoma prognostication; leaves open added value of molecular markers.
Cohort (n=45)
Classic prognostic factors such as tumor stage, size, and grade are the strongest predictors of survival in synovial sarcoma, while SYT-SSX fusion type and ezrin expression do not provide additional prognostic value.
Heuvel et al. (2009) conducted a cohort in Synovial sarcoma (n=45). Prognostic factors (tumor stage, tumor size, tumor grade) was evaluated on Disease-specific survival (DSS) and metastasis-free survival (MFS). Disease stage at presentation, tumor size >5 cm, and histologic grade 3 were significant predictors of worse disease-specific and metastasis-free survival in synovial sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: